Top

Annals of Hematology

Published in:

23-11-2023 | Anemia | Letter to the Editor

Diamond-Blackfan anemia with very late and fatal onset aplasia in a 55-year-old patient with RPL11 mutation

Authors: Bernhard Strasser, Sonja Heibl, Gregor Hörmann, Alexander Haushofer

Published in: Annals of Hematology | Issue 3/2024

Excerpt

Dear editor, …

Wu X, Cheng L, Liu X, Sun Y, Li B, He G, Li J (2022) Clinical characteristics and outcomes of 100 adult patients with pure red cell aplasia. Ann Hematol 101(7):1493–1498. https://doi.org/10.1007/s00277-022-04847-2CrossRefPubMed

Vlachaki E, Diamantidis MD, Klonizakis P, Haralambidou-Vranitsa S, Ioannidou-Papagiannaki E, Klonizakis I (2012) Pure red cell aplasia and lymphoproliferative disorders: an infrequent association. ScientificWorldJournal 2012:475313. https://doi.org/10.1100/2012/475313CrossRefPubMedPubMedCentral

Gurnari C, Maciejewski JP (2021) How I manage acquired pure red cell aplasia in adults. Blood 137(15):2001–2009. https://doi.org/10.1182/blood.2021010898CrossRefPubMedPubMedCentral

Shimazu Y, Mizumoto C, Chonabayashi K, Hanyu Y, Kanda J, Takaori-Kondo A (2023) Successful treatment with cyclosporine of pure red cell aplasia induced by obinutuzumab bendamustine therapy. Ann Hematol 102(8):2291–2292. https://doi.org/10.1007/s00277-023-05215-4CrossRefPubMed

Means RT Jr (2016) Pure red cell aplasia. Blood 128(21):2504–2509. https://doi.org/10.1182/blood-2016-05-717140CrossRefPubMed

Martin ES, Ferrer A, Mangaonkar AA, Khan SP, Kohorst MA, Joshi AY, Hogan WJ, Olteanu H, Moyer AM, Al-Kali A, Tefferi A, Chen D, Wudhikarn K, Go R, Viswanatha D, He R, Ketterling R, Nguyen PL, Oliveira JL, Gangat N, Lasho T, Patnaik MM (2021) Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromes. Am J Hematol 96(11):1450–1460. https://doi.org/10.1002/ajh.26321CrossRefPubMed

Quarello P, Garelli E, Carando A, Brusco A, Calabrese R, Dufour C, Longoni D, Misuraca A, Vinti L, Aspesi A, Biondini L, Loreni F, Dianzani I, Ramenghi U (2010) Diamond-Blackfan anemia: genotype-phenotype correlations in Italian patients with RPL5 and RPL11 mutations. Haematologica 95(2):206–213. https://doi.org/10.3324/haematol.2009.011783CrossRefPubMed

Da Costa L, Leblanc T, Mohandas N (2020) Diamond-Blackfan anemia. Blood 136(11):1262–1273. https://doi.org/10.1182/blood.2019000947CrossRefPubMedPubMedCentral

Mars-Holt E, Murdoch A, Frugoli A, Utz B, Kong L (2022) Adult-onset Diamond-Blackfan Anemia with RPL11 Gene Variation Case Report. Am J Case Rep 23:e932649. https://doi.org/10.12659/AJCR.932649CrossRefPubMedPubMedCentral

10.

Flores Ballester E, Gil-Fernandez JJ, Vazquez Blanco M, Mesa JM, de Dios Garcia J, Tamayo AT, Burgaleta C (2015) Adult-onset Diamond-Blackfan anemia with a novel mutation in the exon 5 of RPL11: too late and too rare. Clin Case Rep 3(6):392–395. https://doi.org/10.1002/ccr3.240CrossRefPubMedPubMedCentral

Title: Diamond-Blackfan anemia with very late and fatal onset aplasia in a 55-year-old patient with RPL11 mutation
Authors: Bernhard Strasser
Sonja Heibl
Gregor Hörmann
Alexander Haushofer
Publication date: 23-11-2023
Publisher: Springer Berlin Heidelberg
Keywords: Anemia
Erythrocyte Transfusion
Published in: Annals of Hematology / Issue 3/2024
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-023-05553-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2024

Reduced-intensity allogenic transplantation for children and adolescents with Philadelphia chromosome-positive acute lymphoblastic leukemia

The indirect effects of CMV reactivation on patients following allogeneic hematopoietic stem cell transplantation: an evidence mapping

Refractory hemophagocytic lymphohistiocytosis secondary to polatuzumab vedotin plus rituximab and bendamustine

Tislelizumab monotherapy in patients with previously untreated early-stage classical Hodgkin lymphoma: a real-world study

Heavily pretreated patient with nodal marginal zone lymphoma successfully treated with mosunetuzumab

Philadelphia chromosome-positive B cell acute lymphoblastic phase arising 24 years after treatment-free remission for chronic myeloid leukemia with identical BCR-ABL fusion transcript

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials